Search

Your search keyword '"Bjørge, Line"' showing total 314 results

Search Constraints

Start Over You searched for: Author "Bjørge, Line" Remove constraint Author: "Bjørge, Line" Language english Remove constraint Language: english
314 results on '"Bjørge, Line"'

Search Results

2. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

3. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

4. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

6. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

8. Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

10. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

12. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples

13. A national precision cancer medicine implementation initiative for Norway

14. Secondary Cytoreductive Surgery in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer: A Systematic Review of Randomized Controlled Trials.

15. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.

19. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

23. Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors.

24. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.

27. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

28. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

31. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

32. Shared heritability and functional enrichment across six solid cancers

33. Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study.

34. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study

36. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

37. Molecular and phenotypic characteristics influencing the degree of cytoreduction in high‐grade serous ovarian carcinomas.

38. Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study.

39. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.

40. The WID‐EC test for the detection and risk prediction of endometrial cancer.

43. Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins.

49. Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies.

50. Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes.

Catalog

Books, media, physical & digital resources